Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%–30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively inves...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Mol Sci
Main Authors: Falvella, Felicia Stefania, Caporale, Marta, Cheli, Stefania, Martinetti, Antonia, Berenato, Rosa, Maggi, Claudia, Niger, Monica, Ricchini, Francesca, Bossi, Ilaria, Di Bartolomeo, Maria, Sottotetti, Elisa, Bernardi, Francesca Futura, de Braud, Filippo, Clementi, Emilio, Pietrantonio, Filippo
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2015
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425114/
https://ncbi.nlm.nih.gov/pubmed/25906475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms16048884
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados